查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403514

2030 年肌肉鬆弛劑市場預測：按藥物類型、劑型、給藥途徑、通路、應用、最終用戶和地區進行的全球分析

Muscle Relaxant Drug Market Forecasts to 2030 - Global Analysis By Drug Type, Dosage Form, Route Of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球肌肉鬆弛劑市場規模為 39 億美元，預計到 2030 年將達到 60.3 億美元，預測期內複合年成長率為 6.3%。

肌肉鬆弛劑作用於中樞神經系統，針對神經肌肉接頭、脊髓和大腦的特定區域，調節與肌肉收縮相關的訊號。肌肉鬆弛劑可有效緩解與拉傷、扭傷和受傷等疾病相關的肌肉骨骼疼痛。這些藥物用於治療多種醫療狀況，包括疼痛管理，例如神經病變引起的痙攣、肌肉骨骼損傷和某些類型的慢性疼痛。

根據2021年全球疾病負擔（GBD）資料，全球有17.1億人患有類風濕性關節炎、頸部不適、腰痛、骨折和其他損傷等肌肉骨骼疾病。

老年人口增加

老年人口的增加是肌肉鬆弛劑市場的主要驅動力，加速了需求。隨著世界人口高齡化，與老齡化相關的肌肉骨骼疾病（例如關節炎、慢性疼痛和退化性疾病）的盛行率不斷增加。這些疾病通常會導致肌肉僵硬、痙攣和不適，需要醫療干預來緩解疼痛並提高運動表現。肌肉鬆弛劑透過緩解肌肉痙攣、減輕疼痛和改善身體功能，在滿足這些需求方面發揮重要作用。

副作用

與肌肉鬆弛劑相關的副作用的普遍存在是肌肉鬆弛劑市場的一個重要抑制因素並阻礙其成長。常見的副作用包括嗜睡、頭暈以及可能與其他藥物的相互作用，影響患者的醫囑遵從性和對治療的整體滿意度。然而，圍繞肌肉鬆弛劑的安全性擔憂使得醫療保健專業人員對開立這些藥物猶豫不決，特別是對於某些患者群體，例如老年人和患有併發症的患者。

增加久坐的生活方式

久坐生活方式的增加是肌肉鬆弛劑市場的關鍵促進因素。現代社會趨勢的特徵是長時間坐著、文書工作和有限的體力活動，導致肌肉骨骼問題的增加。此外，久坐的生活方式與肌肉痙攣、拉傷和慢性疼痛等症狀有關，這就需要使用肌肉鬆弛劑來緩解症狀，從而推動市場需求。

替代治療方法的可用性

患者和醫療保健提供者擴大尋求非藥物干預措施，例如物理治療、針灸和運動療法，作為肌肉鬆弛劑的有效治療方法替代方案。此外，患者擴大尋求促進整體健康並減少藥物干預需求的療法。替代治療方法的可用性是阻礙市場擴張的主要因素。

COVID-19 的影響

大流行的早期階段擾亂了藥品供應鏈，影響了肌肉鬆弛劑的生產和分銷。然而，隨著醫療保健系統適應不斷變化的環境，有效疼痛管理和肌肉相關干預措施的需求推動了市場的復甦。大流行引起的生活方式的改變，例如久坐行為的增加和壓力引起的肌肉緊張，導致了對肌肉鬆弛劑的持續需求。

預計注射劑市場在預測期內將是最大的市場

注射劑領域估計佔最大佔有率。注射給藥途徑在旨在誘導肌肉鬆弛的治療劑的遞送中起著關鍵作用。可注射的肌肉鬆弛劑例如透過肌肉或靜脈注射直接給藥到血流或目標肌肉組織。此途徑具有起效快、給藥控制精確等優點，增加了肌鬆藥的需求。

骨骼肌鬆弛劑領域預計在預測期內複合年成長率最高

骨骼肌鬆弛劑領域預計將在預測期內出現良好的成長。這些藥物作用於脊髓或大腦層面的中樞神經系統，緩解肌肉痙攣、僵硬和相關不適。骨骼肌鬆弛劑的治療用途多種多樣，從治療肌肉骨骼疾病和痙攣到促進外科手術和增強物理治療的效果。此外，在手術環境中，骨骼肌鬆弛劑可用作麻醉輔助劑，促進插管，並最大限度地減少手術期間的不自主肌肉運動。

比最大的地區

由於肌肉骨骼疾病盛行率上升、醫療保健服務意識和可近性不斷提高，亞太地區在預測期內佔據了最大的市場佔有率。亞太地區多樣化的醫療保健模式表明，人們越來越接受非侵入性治療方法，包括用於治療和美容目的的肌肉鬆弛劑。此外，該地區的經濟發展提高了醫療保健支出的能力，並支持創新製藥解決方案的採用。

複合年成長率最高的地區：

由於強大的醫療基礎設施、技術進步和肌肉骨骼疾病的高盛行率，預計歐洲在預測期內將出現有益成長。該地區人口高齡化以及關節炎和肌肉僵硬等與老齡化相關的疾病的流行極大地增加了對肌肉鬆弛劑的需求。此外，該地區的醫療保健系統優先考慮以患者為中心的護理，並有助於探索肌肉骨骼疾病的創新治療方案。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球肌肉鬆弛劑市場：依藥物類型

  • 神經肌肉阻斷劑
  • 骨骼肌鬆弛劑
  • 臉部肌肉鬆弛劑

第6章全球肌肉鬆弛劑市場：按劑型

  • 膠囊
  • 藥片
  • 液體
  • 噴
  • 凝膠/軟膏

第7章全球肌肉鬆弛劑市場：依給藥途徑

  • 注射
  • 口服
  • 其他給藥途徑

第8章全球肌肉鬆弛劑市場：依配銷通路

  • 零售藥房
  • 網路藥房
  • 醫院藥房

第9章全球肌肉鬆弛劑市場：依應用分類

  • 肌肉骨骼疾病
  • 肌肉痙攣和疼痛緩解
  • 外科手術
  • 其他用途

第10章全球肌肉鬆弛劑市場：依最終用戶分類

  • 專科診所
  • 醫院
  • 居家護理
  • 其他最終用戶

第11章全球肌肉鬆弛劑市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • Mylan
  • Novartis AG
  • Ipsen Biopharmaceuticals, Inc.
  • Pfizer Inc
  • Merz Pharmaceuticals, LLC.
  • Vertical Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sanofi
  • Teva Pharmaceuticals Industries Ltd, Inc.
  • Par Pharmaceutical
  • Sun Pharmaceutical Industries Ltd.
  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
Product Code: SMRC24739

According to Stratistics MRC, the Global Muscle Relaxant Drug Market is accounted for $3.9 billion in 2023 and is expected to reach $6.03 billion by 2030 growing at a CAGR of 6.3% during the forecast period. Muscle relaxant drugs act on the central nervous system, targeting neuromuscular junctions, the spinal cord, or specific areas of the brain to modulate signals involved in muscle contraction. Muscle relaxants are effective in providing relief from musculoskeletal pain associated with conditions such as strains, sprains, and injuries. These drugs are utilized in various medical conditions, including the management of conditions such as spasticity resulting from neurological disorders, musculoskeletal injuries, and certain types of chronic pain.

According to a study of Global Burden of Disease (GBD) 2021 data, 1.71 billion individuals globally suffer from musculoskeletal diseases, such as osteoarthritis, rheumatoid arthritis, neck discomfort, low back pain, fractures, and other injuries.

Market Dynamics:

Driver:

Growing geriatric population

The growing geriatric population is a significant driver in the muscle relaxant drug market, accelerating the demand. As the global population ages, there is an increased prevalence of age-related musculoskeletal conditions, such as arthritis, chronic pain, and degenerative disorders. These conditions often result in muscle stiffness, spasms, and discomfort, requiring medical intervention for pain relief and improved mobility. Muscle relaxant drugs play a crucial role in addressing these needs by providing relief from muscle spasms, reducing pain and improving physical function.

Restraint:

Side effects

The prevalence of side effects associated with muscle relaxant drugs stands as a substantial restraint in the muscle relaxant drug market, hampering its growth. Common side effects include drowsiness, dizziness, and potential interactions with other medications, impacting patient adherence and overall satisfaction with treatment. However, safety concerns surrounding muscle relaxants can lead to hesitancy among healthcare providers in prescribing these drugs, especially to certain patient populations, such as the elderly or those with co-morbidities.

Opportunity:

Rising prevalence of sedentary lifestyles

The increasing prevalence of sedentary lifestyles serves as a significant driver for the muscle relaxant drug market. Modern societal trends, characterized by prolonged periods of sitting, desk-bound work and limited physical activity, contribute to a rise in musculoskeletal issues. Furthermore, sedentary lifestyles are linked to conditions such as muscle spasms, strains, and chronic pain, necessitating the use of muscle relaxant drugs for symptomatic relief, which enhances market demand.

Threat:

Availability of alternative treatment modalities

Patients and healthcare providers increasingly explore non-pharmacological interventions, such as physical therapy, acupuncture, and exercise regimens, as viable alternatives to muscle relaxant drugs. Moreover, patients are becoming more proactive in seeking therapies that promote overall well-being and mitigate the need for pharmacological interventions. The availability of alternative treatment modalities is a significant restraint hindering market expansion.

COVID-19 Impact

The initial phase of the pandemic led to disruptions in the pharmaceutical supply chain, affecting the production and distribution of muscle relaxant drugs. However, as healthcare systems adapted to the evolving circumstances, the market witnessed a resurgence driven by the need for effective pain management and muscle-related interventions. The pandemic-induced lifestyle changes, including increased sedentary behaviors and stress-related muscle tension, contributed to a sustained demand for muscle relaxant medications.

The Injectable segment is expected to be the largest during the forecast period

The Injectable segment is estimated to hold the largest share. The Injectable route of administration plays a pivotal role in the delivery of therapeutic agents designed to induce muscle relaxation. Injectable muscle relaxants are administered directly into the bloodstream or targeted muscle tissues through methods such as intramuscular or intravenous injections. This route offers several advantages, including a quick onset of action and accurate dosage control, which enhances the demand for muscle relaxant drugs.

The skeletal muscle relaxant drugs segment is expected to have the highest CAGR during the forecast period

The skeletal muscle relaxant drugs segment is anticipated to have lucrative growth during the forecast period. These drugs act on the central nervous system, either at the spinal cord or brain levels, to alleviate muscle spasms, stiffness, and associated discomfort. The therapeutic applications of skeletal muscle relaxants are diverse, ranging from the management of musculoskeletal conditions and spasticity to facilitating surgical procedures and promoting physical therapy outcomes. Moreover, in surgical settings, skeletal muscle relaxants find utility as adjuncts to anaesthesia, facilitating intubation and minimizing involuntary muscle movements during procedures.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to rising prevalence of musculoskeletal disorders and increasing awareness and accessibility to healthcare services. The Asia-Pacific region's diverse healthcare landscape witnesses a growing acceptance of non-invasive treatment modalities, including muscle relaxants, both for therapeutic and cosmetic purposes. Additionally, the region's economic development results in an increasing capacity for healthcare spending, supporting the adoption of innovative pharmaceutical solutions.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period, due to robust healthcare infrastructure, technological advancements, and a high prevalence of musculoskeletal disorders. The region's aging population contributes significantly to the demand for muscle relaxant drugs as age-related conditions, such as arthritis and muscle stiffness, become more prevalent. Moreover, the region's healthcare systems prioritize patient-centric care, contributing to the exploration of innovative treatment options for musculoskeletal conditions.

Key players in the market:

Some of the key players in the Muscle Relaxant Drug Market include Mylan, Novartis AG, Ipsen Biopharmaceuticals, Inc., Pfizer Inc, Merz Pharmaceuticals, LLC., Vertical Pharmaceuticals, Amneal Pharmaceuticals LLC, Sanofi, Teva Pharmaceuticals Industries Ltd, Inc., Par Pharmaceutical, Sun Pharmaceutical Industries Ltd., Abbott Laboratories and F. Hoffmann-La Roche AG.

Key Developments:

In Mar 2023, Abbott partners with Medinbox to increase efficiency in electrophysiology labs and strengthen information sharing among physicians to drive improved patient care.

In June 2022, Novartis announced a partnership with the American Society of Hematology (ASH) to provide six additional African nations with technology that is already being used in Ghana to document and share the diagnosis of babies with sickle cell disease.

In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Drug Types Covered:

  • Neuromuscular Blocking Agents
  • Skeletal Muscle Relaxant Drugs
  • Facial Muscle Relaxant Drugs

Dosage Forms Covered:

  • Capsule
  • Tablet
  • Liquid
  • Sprays
  • Gel and Ointments

Route Of Administrations Covered:

  • Injectable
  • Oral
  • Other Route Of Administration

Distribution Channels Covered:

  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy

Applications Covered:

  • Musculoskeletal Disorders
  • Muscle Spasm & Pain Relief
  • Surgery
  • Other Applications

End Users Covered:

  • Specialty Clinics
  • Hospitals
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Muscle Relaxant Drug Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Neuromuscular Blocking Agents
  • 5.3 Skeletal Muscle Relaxant Drugs
  • 5.4 Facial Muscle Relaxant Drugs

6 Global Muscle Relaxant Drug Market, By Dosage Form

  • 6.1 Introduction
  • 6.2 Capsule
  • 6.3 Tablet
  • 6.4 Liquid
  • 6.5 Sprays
  • 6.6 Gel and Ointments

7 Global Muscle Relaxant Drug Market, By Route Of Administration

  • 7.1 Introduction
  • 7.2 Injectable
  • 7.3 Oral
  • 7.4 Other Route Of Administration

8 Global Muscle Relaxant Drug Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Online Pharmacy
  • 8.4 Hospital Pharmacy

9 Global Muscle Relaxant Drug Market, By Application

  • 9.1 Introduction
  • 9.2 Musculoskeletal Disorders
  • 9.3 Muscle Spasm & Pain Relief
  • 9.4 Surgery
  • 9.5 Other Applications

10 Global Muscle Relaxant Drug Market, By End User

  • 10.1 Introduction
  • 10.2 Specialty Clinics
  • 10.3 Hospitals
  • 10.4 Homecare
  • 10.5 Other End Users

11 Global Muscle Relaxant Drug Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Mylan
  • 13.2 Novartis AG
  • 13.3 Ipsen Biopharmaceuticals, Inc.
  • 13.4 Pfizer Inc
  • 13.5 Merz Pharmaceuticals, LLC.
  • 13.6 Vertical Pharmaceuticals
  • 13.7 Amneal Pharmaceuticals LLC
  • 13.8 Sanofi
  • 13.9 Teva Pharmaceuticals Industries Ltd, Inc.
  • 13.10 Par Pharmaceutical
  • 13.11 Sun Pharmaceutical Industries Ltd.
  • 13.12 Abbott Laboratories
  • 13.13 F. Hoffmann-La Roche AG

List of Tables

  • Table 1 Global Muscle Relaxant Drug Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Muscle Relaxant Drug Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Muscle Relaxant Drug Market Outlook, By Neuromuscular Blocking Agents (2021-2030) ($MN)
  • Table 4 Global Muscle Relaxant Drug Market Outlook, By Skeletal Muscle Relaxant Drugs (2021-2030) ($MN)
  • Table 5 Global Muscle Relaxant Drug Market Outlook, By Facial Muscle Relaxant Drugs (2021-2030) ($MN)
  • Table 6 Global Muscle Relaxant Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 7 Global Muscle Relaxant Drug Market Outlook, By Capsule (2021-2030) ($MN)
  • Table 8 Global Muscle Relaxant Drug Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 9 Global Muscle Relaxant Drug Market Outlook, By Liquid (2021-2030) ($MN)
  • Table 10 Global Muscle Relaxant Drug Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 11 Global Muscle Relaxant Drug Market Outlook, By Gel and Ointments (2021-2030) ($MN)
  • Table 12 Global Muscle Relaxant Drug Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 13 Global Muscle Relaxant Drug Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 14 Global Muscle Relaxant Drug Market Outlook, By Oral (2021-2030) ($MN)
  • Table 15 Global Muscle Relaxant Drug Market Outlook, By Other Route Of Administration (2021-2030) ($MN)
  • Table 16 Global Muscle Relaxant Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Muscle Relaxant Drug Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 18 Global Muscle Relaxant Drug Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 19 Global Muscle Relaxant Drug Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 20 Global Muscle Relaxant Drug Market Outlook, By Application (2021-2030) ($MN)
  • Table 21 Global Muscle Relaxant Drug Market Outlook, By Musculoskeletal Disorders (2021-2030) ($MN)
  • Table 22 Global Muscle Relaxant Drug Market Outlook, By Muscle Spasm & Pain Relief (2021-2030) ($MN)
  • Table 23 Global Muscle Relaxant Drug Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 24 Global Muscle Relaxant Drug Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global Muscle Relaxant Drug Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Muscle Relaxant Drug Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 27 Global Muscle Relaxant Drug Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Muscle Relaxant Drug Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 29 Global Muscle Relaxant Drug Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.